Nanotechnology platforms; an innovative approach to brain tumor therapy

Medicinal Chemistry

Volumn 7, Issue 5, 2011, Pages 488-503

  Nair, Baiju G ^a   Varghese, Saino Hanna ^a   Nair, Remya ^a   Yoshida, Yasuhiko ^a   Maekawa, Toru ^a   Kumar, D Sakthi ^a  

^a TOYO UNIVERSITY   (Japan)

Author keywords

Blood Brain Barrier; Brain tumor; Carbon nanotubes; Chemotherapy; Nanodrug delivery; Nanoparticles; Neutron capture therapy; Photodynamic therapy; RNAi; Targeting ligands

Indexed keywords

APTAMER; CARBON NANOTUBE; FULLERENE DERIVATIVE; GOLD; NANOPARTICLE; QUANTUM DOT;

BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER THERAPY; DRUG DELIVERY SYSTEM; HUMAN; NANOTECHNOLOGY; NEUTRON CAPTURE THERAPY; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NANOMEDICINE; NANOPARTICLES;

EID: 80051992402     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340611796799113     Document Type: Review

References (169)

1. Cuenca, A. G.; Jiang, H.; Hochwald, S. N.; Delano, M.; Cance, W. G.; Grobmyer, S. R. Emerging Implications of Nanotechnology on Cancer Diagnostics and Therapeutics. Cancer, 2006, 107, 459-466. (Pubitemid 44107204)
2. Ferrari, M. Cancer nanotechnology opportunities and challenges. Nat. Rev. Cancer, 2005, 5, 161-171.
3. Wagner, V.; Dullaart, A.; Bock, A.-K.; Zweck, A. The emerging nanomedicine landscape. Nat. Biotechnol., 2006, 24, 1211-1217. (Pubitemid 44564760)
4. Jones, D. Cancer nanotechnology: small, but heading for the big time. Nat. Rev. Drug Discov., 2007, 6, 174-175.
5. Koo, Y. E.; Reddy, G. R.; Bhojani, M.; Schneider, R. Brain cancer diagnosis and therapy with nanoplatforms. Adv. Drug Deliv. Rev., 2006, 58, 1556-1557
6. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer., 2002, 2, 48-58. (Pubitemid 37328807)
7. Larsen, A. K.; Escargueil, A. E.; Skladanowski, A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther., 2000, 85, 217-229. (Pubitemid 30160791)
8. Tanaka, T.; Decuzzi, P.; Cristofanilli, M.; Sakamoto, J. H.; Tasciotti, E.; Robertson, F. M.; Ferrari, M. Nanotechnology for breast cancer therapy. Biomed Microdevices., 2009, 11, 49-63.
9. Tasciotti, E.; Liu, X.; Bhavane, R.; Plant, K.; Leonard, A. D.; Price, B. K.; Cheng, M. M.; Decuzzi P.; Tour J. M.; Robertson F.; Ferrari M. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol., 2008, 3, 151-157. (Pubitemid 351355132)
10. Suh, W. H.; Suh, Y. H.; Stucky, G. D. Multifucntional nanosystems at the interface of physical and life sciences. Nano Today, 2009, 4, 27-36.
11. Jabr-Milane L. S.; van Vlerken L. E.; Yadav S.; Amiji M. M. Multifunctional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev., 2008, 34, 592-602.
12. Feneque, J. The Importance of using rodents in the Nanomedical Research. Nano Delta. 2005.
13. Maier-Hauff, K.; Rothe, R.; Scholz, R.; Gneveckow, U.; Wust, P.; Thiesen, B.; Feussner, A.; von Deimling, A.; Waldoefner, N.; Felix, R.; Jordan, A. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J. Neurooncol., 2007, 81, 53-60 (Pubitemid 44963989)
14. Vescovi, A. L.; Galli, R.; Brent A. Reynolds. Brain tumour stem cells. Nat. Rev. Cancer., 2006, 6, 425-436.
15. Brandes, A. A.; Tosoni, A.; Franceschi, E.; Reni, M.; Gatta, G.; Vecht, C. Glioblastoma in adults. Crit. Rev. Oncol.. Hematol., 2008, 67, 139-152.
16. Pardridge, W. M. Blood-brain barrier drug targeting: The future of brain drug develpoement. Mol. Interv., 2003, 3, 91-105.
17. Nies, A. T. The role of membrane transporters in drug delivery to brain tumors. Cancer Lett., 2007, 254, 11-29. (Pubitemid 47058801)
18. Kemper, E. M.; Boogerd, W.; Thuis, I.; Beijnen, J. H.; van Tellingen, O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumors? Cancer Treat Rev., 2004, 30, 415-423. (Pubitemid 38968122)
19. Suri, S, S.; Fenniri, H.; Singh, B. Nanotechnology based drug delivery systems. J. Occupol. Med. Toxicol., 2007, 2, 1-16.
20. Kreuter, J.; Gelprina, S. Use of nanoparticles for cerebral cancer. Tumori., 2008, 94(2), 271-277. (Pubitemid 351838835)
21. Oberdörster, G.; Oberdörster E, Oberdörster, J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005, 113, 823-39. (Pubitemid 40984181)
22. Schneider, G. F.; Subr, V.; Ulbrich, K.; Decher, G. Multifunctional cytotoxic stealth nanoparticles. A model approach with potential for cancer therapy. Nano Lett., 2009, 9, 636-642.
23. Panchagnula, R. Pharmaceutical aspects of paclitaxel. Int. J. Pharm., 1998, 172, 1-15. (Pubitemid 28430240)
24. Gallo, J. M.; Li, S.; Guo, P.; Reed, K.; Ma, J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res., 2003, 63, 5114-5117. (Pubitemid 37022652)
25. Zhao, M.; Liang, C.; Li, A.; Chang, J.; Wang, H.; Yan, R.; Zhang, J.; Tai, J. Magnetic paclitaxel nanoparticles inhibit glioma growth and improve the survival of rats bearing glioma xenografts. Anticancer Res. 2010, 30, 2217-2223.
26. Ashley, N.; Poulton, J. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem Biophys Res Commun. 2009, 378, 450-455.
27. Zara, G. P.; Bargoni, A.; Cavalli, R.; Fundarò, A.; Vighetto, D.; Gasco, M. R. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci., 2002, 91, 1324-33. (Pubitemid 34651194)
28. Lu, W.; Wan, J.; Zhang, Q.; She, Z.; Jiang, X. Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats. Int J Cancer. 2007, 120, 420-31. (Pubitemid 44956856)
29. Gupta, B.; Torchilin, V. P. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother. 2007, 56, 1215-1223. (Pubitemid 46763936)
30. Madhankumar, A. B.; Slagle-Webb, B.; Mintz, A.; Sheehan, J. M.; Connor, J. R. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for Glioblastoma multiforme. Mol Cancer Ther. 2006, 5, 3162-3169. (Pubitemid 46092059)
31. Barth, R.; Yang, W.; Adams, D. M.; Rotaru, J. H.; Shukla, S.; Sekido, M.; Tjarks, W.; Fenstermaker, R. A.; Ciesielski, M.; Nawrocky, M. M.; Coderre, J. A. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 2002, 62, 3156-3159
32. Hermanson, M.; Funa, K.; Hartman, M.; Claesson-Welsh L.; Heldin C. H.; Westermark, B.; Nistér, M. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992, 52, 3213-3219
33. Morrison, R.; Yamaguchi, F.; Bruner, J.; Tang, M.; Mckeehan, W.; Berger, M. Fibroblast growth factor receptor gene expression and immuno reactivity are elevated in human Glioblastoma multiforme. Cancer Res. 1994, 54, 2794-2799 (Pubitemid 24173776)
34. Mineo, J. F.; Bordron, A.; Quintin-Roué, I.; Maurage, C. A.; Buhé, V.; Loisel, S.; Dubois, F.; Blond, S.; Berthou C. Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new Nude mice model. J. Neurooncol. 2006, 76, 249-255
35. Mineo, J. F.; Bordron, A.; Roue, Q.; Loisel, S.; Ster, K.L.; Buhe, V.; Lagarde, N.; Berthou, C. Recombinant humanized anti-HER2/neu antibody (Herceptins) induces cellular death of Glioblastomas. Br J Cancer. 2004, 91, 1195-1199 (Pubitemid 39336262)
36. Mintz, A.; Gibo, D.; Slagle-Webb, B.; Debinski, W. IL-13R alpha 2 is a glioma-restricted receptor for interleukin-13. Neoplasia 2002, 4, 388-399. (Pubitemid 34976954)
37. Saul, J. M.; Annapragada, A. V.; Bellamkonda, R. A. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. controlled Release 2006, 114, 277-287 (Pubitemid 44310813)
38. Shuayev, V. I.; Pisanic, T. R 2nd.; Jin, S. Magnetic nanoparticles for theragnostics. Adv. Drug Deliv Rev. 2009, 61, 467-477
39. Figuerola.; A, Di Corato, R.; Manna, L.; Pellegrin, T. From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res., 2010, 62, 126-4
40. Nair, B. G.; Nagaoka, Y.; Morimoto, H.; Yoshida, Y.; Maekawa, T.; Kumar, D. S. Aptamer conjugated magnetic nanoparticles as nanosurgeons. Nanotechnology. 2010, 21, 455102
41. Mykhaylyk, O.; Cherchenko, A.; Ilkin, A.; Dudchenko, N.; Ruditsa, V.; Novoseletz, M.; Zozulya, Yu. Glial brain tumor targeting of magnetite nanoparticles in rats. J. Magn. Magn. Mater., 2001, 225, 241-247 (Pubitemid 32335303)
42. Ren Hunag, B.; Yuan Chen, P.; Chiung-Yin, H.; Shih-Ming, J.; Yunn-Hwa, M.; Tony W.; Jyh-Ping C.; Kuo-Chen, W. Bioavailability of magnetic nanoparticles to the brain. J. Magn. Magn. Mater., 2009, 321, 1604-1609
43. Sun, C.; Veiseh, O.; Gunn, J.; Fang, C. In vivo MRI detection of Gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small, 2008, 4, 372-379 (Pubitemid 351421268)
44. Veiseh, O.; Sun, C.; Fang, C.; Bhattarai, N.; Gunn, J.; Kievit, F.; Du, K.; Pullar, B.; Lee, D.; Ellenbogen, R.G.; Olson, J.; Zhang, M. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 2009, 69, 6200-6207
45. Kobayashi, T.; Kida, Y.; Tanaka, T.; Hattori, K.; Matsui, M.; Amemiya Y. Interstitial hyperthermia of malignant brain tumors by implant heating system: Clinical experiment. J. Neurooncol, 1984, 10, 153-163.
46. Hildebrandt, B.; Wust, P.; Ahlers, O.; Dieing, A.; Sreenivasa, G. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol. 2003, 43, 33-56. (Pubitemid 34722786)
47. Barrera, C.; Herrera, A.; Zayas, A.; Rinaldi, C. Surface modification of magnetic nanoparticles for biomedical applications. J. Magn. Magn. Mater., 2009, 321, 1397-1399.
48. Ito, A.; Shinkai, M.; Honda, H.; Yoshikawa, K.; Saga, S.; Wakabayashi, T.; Yoshida, J.; Kobayashi, T. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 2003, 52, 80-88. (Pubitemid 36337615)
49. Ito, A.; Matsuoka, F.; Honda, H.; Kobayashi. T. Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles. Cancer Gene Ther., 2003, 10(12), 918-925. (Pubitemid 37532338)
50. Maier-Hauff, K.; Ulrich, F.; Nestler, D.; Niehoff, H.; Wust, P.; Thiesen, B.; Orawa, H.; Budach, V., Jordan, A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 2011, 103(2), 317-324.
51. Bhattacharya, R.; Mukherjee, P. Biological properties of "naked" metal nanoparticles. Adv. Drug Deliv Rev., 2008, 60, 1289-1306.
52. Patra, H. K.; Banerjee, S.; Chaudhuri, U.; Lahiri, P.; Dasgupta, A. K. Cell selective response to gold nanoparticles. Nanomedicine, 2007, 3, 111-119. (Pubitemid 46899618)
53. Ghosh, P.; Han, G.; De, M.; Kim, C. K.; Rotello, V. M. Gold nanoparticles in delivery applications. Adv. Drug Deliv Rev. 2008, 60, 1307-1315.
54. Woude, G. F.; Kelloff, G. J.; Ruddon, R. W.; Koo, H. M., Sigman, C. C.; Barrett, J. C.; Day, R. W.; Dicker, A. P.; Kerbel, R. S.; Parkinson, D. R.; Slichenmyer, W. J. Reanalysis of cancer drugs: old drugs, new tricks. Clin. Cancer Res. 2004, 10, 3897-3907. (Pubitemid 38697626)
55. Kerbel, R. S. Antiangiogenic drugs and current strategies for the treatment of lung cancer. Semin. Oncol., 2004, 31, 54-60. (Pubitemid 38241021)
56. Kerbel, R. S.; Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy, Nat. Rev. Cancer., 2004, 4, 423-436. (Pubitemid 38745528)
57. Basu, S.; Nagy, A. J.; Atala, A.; Mukhopadhyay, D.; Soker, S. Antiangiogenic Properties of Gold Nanoparticles. Clin Cancer Res., 2005, 11, 3530-34. (Pubitemid 40627908)
58. Kemp, M. M.; Kumar, A.; Mousa, S.; Dyskin, E.; Yalcin, M.; Ajayan, P.; Linhardt, R. J.; Mousa, S. A. Gold and silver nanoparticles conjugated with heparin derivative possessanti-angiogenesis properties. Nanotechnology, 2009, 20, 455104.
59. Kang, B.; Mackey, M. A.; El-Sayed, M. A. Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. J. Am. Chem. Soc, 2010, 132, 1517-1519.
60. Chen, J.; D. Wang, D.; Xi, J.; Au, L.; Siekkinen, A.; Warsen, A.; Li, Z. Y.; Zhang, H.; Xia, Y.; Li, X. Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells. Nano Lett., 2007, 7, 1318.
61. Au, L.; Zheng, D.; Zhou, F.; Li, Z. Y.; Li, X.; Xia, Y. A Quantitative study on the photothermal effect of immuno gold nanocages targeted to breast cancer cells. ACS Nano, 2008, 2, 1645-1652.
62. Yang, X.; Skrabalak, S. E.; Li, Z.-Y.; Xia, Y.; Wang, L. V. Photoacoustic tomography of a rat cerebral cortex in vivo with Au nanocages as an optical contrast agent. Nano Lett., 2007, 7, 3798-3802.
63. Chen, J.; Glaus, C.; Laforest, R.; Zhang, Q.; Yang, M.; Gidding, M.; Welch, M. J.; Xia, Y. Gold Nanocages as Photothermal Transducers for CancerTreatment. Small, 2010, 6, 811-817.
64. Zhang, Z. J. Biomedical Applications of shape controlled palsmonic nanostructures: A case study of hollow gold nanospheres for photothermal ablation therapy of cancer. J. Phy. Chemm. Lett., 2010, 1, 686-695.
65. Bernardi, R. J.; Lowery, A. R.; Thompson, P. A.; Blaney, S. M.; West, L. J. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J. Neuro Oncol. 2008, 86, 165-172. (Pubitemid 350263413)
66. Hild, W. A.; Breunig, M.; Goepferich, A. Quantum dots - Nanosized probes for the exploration of cellular and intracellular targeting. Eur. J. Pharm. Biopharm., 2008, 68, 153-168.
67. Azzazy, H. H.; Mansour, M. H.; Kazmierczak, S. C. From diagnostics to therapy: prospects of Quantum dots. Clin Biochem., 2007, 40, 917-927. (Pubitemid 47301793)
68. Tang, M.; Wang, M.; Xing, T.; Zeng, J.; Wang, H.; Ruan, D. Y. Mechanisms of unmodified CdSe quantum dot-induced elevation of cytoplasmic calcium levels in primary cultures of rat hippocampal neurons. Biomaterials, 2008, 29, 4383-4391.
69. Jackson, H.; Muhammad, O.; Daneshvar, H.; Nelms, J.; Popescu, A.; Vogelbaum, M. A.; Bruchez, M.; Toms, S. A. Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas. Neurosurgery, 2007, 60, 524-529. (Pubitemid 46339198)
70. Bailey, J. V.; Easwaran, H.; Zhang, Y.; Griffiths, E.; Belinsky, S. A.; Herman, J. G.; Baylin, S. B.; Carraway, H. E.; Wang, T. H. MS-qFRET: A quantum dot-based method for analysis of DNA methylation. Genome Res. 2009, 19, 1455-1461.
71. Chen, Y.; Huang, L. Expert. Opin. Drug Delivery, 2008, 5, 1301-1311.
72. Davis, M. E.; Zuckerman, J. E.; Choi, C. H.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010, 464, 1067-70.
73. Ozpolat, B.; Sood, A. K.; Lopez-Berestein, G. Nanomedicine based approaches for the delivery of siRNA in cancer. J. Intern Med. 2010, 267, 44-53.
74. Bonoiu, A.; Mahajan, S. D.; Ye, L.; Kumar, R.; Ding, H.; Yong, K. T.; Roy, I.; Aalinkeel, R.; Nair, B.; Reynolds, J. L.; Sykes, D. E.; Imperiale, M. A.; Bergey, E. J.; Schwartz, S. A.; Prasad, P. N. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res., 2009, 1282, 142-155
75. Jung, J.; Solanki, A.; Memoli, K. A.; Kamei, K.; Kim, H.; Drahl, M. A.; Williams, L. J.; Tseng, H. R.; Lee, K. B. Selective inhibition of human brain tumor cells through multifunctional quantum-dotbased siRNA delivery. Angew. Chem. Int. Ed., 2010, 49, 103-107
76. Arndt-Jovin, D. J., Kantelhardt S. R., Caarls W., de Vries, A. H., Giese, A., Jovin Ast, T. M. Tumor-targeted quantum dots can help surgeons find tumor boundaries. IEEE Trans. Nanobioscience. 2009, 8, 65-71
77. Muhammad, O.; Popescu, A.; Toms, S. A. Macrophage-mediated co-localization of quantum dots in experimental glioma. Methods Mol Biol., 2008, 374, 1064-3745
78. Chen, C. X.; Deng, L. Y.; Lin, L.; Pang, W. D.; Qing, H.; Qu, F.; Xie, H. F. Quantum dot-labeled aptamer nanoprobes specifically targeting glioma cells. Nanotechnology, 2008, 19, 235105.
79. Ganta, S.; Amiji, M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm., 2009, 6(3), 928-939.
80. Desai, A.; Vyas T.; Amiji M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J. Pharm Sci. 2008, 97, 2745-56.
81. Janjic, M. J.; Ahrens, T. E. Fluorine-containing nanoemulsions for MRI celltracking. Wiley Interdiscip Rev. Nanomed Nanobiotechnol. 2009, 1, 492-501.
82. Yoshida, J.; Mizuno, M. Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma. J. Neurooncol., 2003, 65, 261-267. (Pubitemid 37526818)
83. Saito, R.; Bringas, J. R.; McKnight, T. R.; Wendland, M. F.; Mamot, C.; Drummond, D. C.; Kirpotin, D. B.; Park, J. W.; Berger, M. S.; Bankiewicz, K. S. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res., 2004, 64, 2572-2579. (Pubitemid 38523915)
84. Saito, R.; Krauze, M. T.; Bringas, J. R.; Noble, C.; McKnight, T. R.; Jackson, P.; Wendland, M. F.; Mamot, C.; Drummond, D. C.; Kirpotin, D. B.; Hong, K.; Berger, M. S.; Park J. W.; Bankiewicz, K. S. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp. Neurol. 2005, 196, 381-9. (Pubitemid 41607827)
85. Kaur, I. P.; Bhandari, R.; Bhandari, S.; Kakkar, V. Potential of solid lipid nanoparticles in brain targeting. J. Controlled Release, 2008, 127, 97-109.
86. Pedersen, N.; Hansen, S.; Heydenreich, A. V.; Kristensen, G. H.; Poulsen, S. H. Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands. Eur. J. Pharm. Biopharm., 2006, 62, 155-162. (Pubitemid 43143267)
87. Del Pozo-Rodríguez A.; Delgado D.; Solinís M. A.; Pedraz J. L.; Echevarría E.; Rodríguez J. M.; Gascón AR. Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int. J. Pharm., 2010, 29, 157-62.
88. Firme, C. P.; Bandaru, P. R. Toxicity issues in the application of carbon nanotubes to biological systems. Nanomedicine, 2010, 6, 245-256.
89. Shao-Yu, C.; Ji-Lie, K. Advance in Research on carbon nanotubes as diagnostic and therapeutic agents for tumor. Chin. J. Anal Chem., 2009, 37, 1240-1246.
90. Foldvari, M.; Bagonluri, M. Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomedicine, 2008, 4, 183-200.
91. Hashimoto A.; Yorimitsu, H.; Ajima, K.; Suenaga, K.; Isobe, H.; Miyawaki, J.; Yudasaka, M.; Iijima, S.; Nakamura, E. Selective deposition of a gadolinium (III) cluster in a hole opening of singlewall carbon nanohorn Proc. Natl. Acad. Sci. USA, 2004, 101, 8527-8530. (Pubitemid 38745803)
92. Hartman K B.; Laus S.; Bolskar R D.; Muthupillai R.; Helm L.; Tóth, É.; Merbach, A. E.; Wilson L. J. Nano Lett., 2008, 8, 415-419.
93. Kam, N. W.; O'Connell, M.; Wisdom, A. J.; Dai, H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl. Acad. Sci. USA, 2005, 102, 11600-11605. (Pubitemid 41170772)
94. Chakravarty, P.; Marches, R.; Zimmerman, N. S.; Swafford, A. D.; Bajaj, P.; Musselman, I. H.; Pantano, P.; Draper, R. K.; Vitetta, E. S. Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes. Proc. Natl. Acad. Sci. USA, 2008, 25, 8697-8702. (Pubitemid 351987743)
95. Pramanik, M.; Swierczewska, M.; Green, D.; Sitharaman, B.; Wang, L. V. Single walled carbon nanotubes as a multimodalthermoacoustic and photoacoustic-contrast agent. J. Biomed Opt., 2009, 14, 034018.
96. Welsher, K.; Liu Z.; Sherlock, S. P.; Robinson, T. J.; Chen, Z.; Daranciang, D.; Dai, H. A route to brightly fluorescent carbon nanotubes for near-infrared imaging in mice. Nat. Nanotechnol., 2009, 4, 773-780.
97. Salvador-Morales, C.; Flahaut, E.; Sim, E.; Sloan, J.; Green, M. L.; Sim, R. B. Complement activation and protein adsorption by carbon nanotubes. Mol. Immunol., 2006, 43, 193-201. (Pubitemid 41384125)
98. Fadel, T. R.; Look, M.; Staffier, P. A.; Haller, G. L.; Pfefferle, L. D.; Fahmy, T. M. Clustering of stimuli on single-walled carbon nanotube bundles enhance cellular Activation. Langmuir, 2010, 26, 5645-5654.
99. Kateb, B.; Handel, M. V.; Zhang, L.; Bronikowski, M. J.; Manohara, H.; Badie, B. Internalization of MWCNTs by microglia: Possible application in immunotherapy of brain tumors. NeuroImage, 2007, 37, S9-S17. (Pubitemid 47239427)
100. Toth, E.; Bolskar, R. D.; Borel, A.; González, G.; Helm, L.; Merbach, A. E.; Sitharaman, B, Wilson, L. J. Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. J. Am. Chem. Soc., 2005, 127, 799-805. (Pubitemid 40178748)
101. Fatouros, P. P.; Corwin, F. D.; Chen, Z.; Broaddus, W. C.; Taturn, J. L.; Kettenmann, B.; Ge, Z.; Gibson, H. W.; Russ, J. L.; Leonard, A. P.; Duchamp, J. C.; Dorn, H. C. In Vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle. Radiology, 2006, 240, 756-764. (Pubitemid 44267332)
102. (3-x) N@C80: An Interleukin-13-conjugated radiolabeled metallofullerene platform. J. Am. Chem. Soc., 2010, 132, 4980-4981.
103. Noble, C. O.; Krauze, M. T.; Drummond, D. C.; Yamashita, Y.; Saito, R.; Berger, M. S.; Kirpotin, D. B.; Bankiewicz, K. S.; Park, J. W. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res., 2006, 66, 2801-2806.
104. Bobo, R. H.; Laske D. W.; Akbasak, A.; Morrison, P. F.; Dedrick, R. L.; Oldfield, E. H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U S A., 1994, 91, 2076-80. (Pubitemid 24092045)
105. Allard, E.; Passirani, C.; Benoit, J. P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials, 2009, 30, 2302-2318.
106. Gilbert, M. R.; Supko, J. G.; Batchelor, T.; Lesser, G.; Fisher, J. D.; Piantadosi, S.; Grossman, S. Phase I clinical and pharmacokinetic study of Irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res., 2003, 9, 2940-2949. (Pubitemid 37006309)
107. Krauze, M. T.; Van den Berg, S. R.; Yamashita, Y.; Saito, R.; Forsayeth, J.; Noble, C.; Park, J.; Bankiewicz, K. S. Safety of real-time convection-enhanced delivery of liposomes to primate brain: A long-term retrospective. Exp Neurol., 2008, 210, 638-644.
108. Perlstein, B.; Ram, Z.; Daniels, D.; Ocherashvilli, A.; Roth, Y.; Margel, S.; Mardor, Y. Convection enhanced deliver of maghemite nanoparticles: Increased efficacy and MRI monitoring. Neuro Oncol., 2008, 10, 153-156.
109. Neeves, K. B.; Lo, C. T.; Foley, C. P.; Saltzman, W. M.; Olbrich, W. L. Fabrication and characterization of microfluidic probes for convection enhanced drug delivery. J. Controlled Release, 2006, 111, 252-262.
110. Mamot C.; Nguyen J. B.; Pourdehnad, M.; Hadaczek, P.; Saito, R.; Bringas, J. R.; Drummond, D. C.; Hong, K.; Kirpotin, D. B.; McKnight, T.; Berger, M. S.; Park, J. W.; Bankiewicz, K. S. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J. Neurooncol., 2004, 68, 1-9. (Pubitemid 39137344)
111. Saito, R.; Krauze, M. T.; Bringas, J. R.; Noble, C.; McKnight, T. R.; Jackson, P.; Wendland, M. F.; Mamot, C.; Drummond, D. C.; Kirpotin, D. B.; Hong, K.; Berger, M. S.; Park, J. W.; Bankiewicz, K. S. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp. Neurol., 2005, 196, 381-38
112. Bidros, D. S.; Liu, J. K.; Vogelbaum, M.A. Future of convectionenhanced delivery in the treatment of brain tumors. Future Oncol., 2010, 6, 117-25.
113. MacKay J. A.; Li, W.; Huang, Z.; Dy, E. E.; Huynh, G.; Tihan, T.; Collins, R.; Deen, D. F.; Szoka, F. C, Jr. HIV TAT Peptide modifies the distribution of DNA nanolipoparticles following convection - enhanced delivery. Mol Ther., 2008, 16, 893-900. (Pubitemid 351587099)
114. Kikuchi, T.; Saito, R.; Sugiyama, S.; Yamashita, Y.; Kumabe, T.; Krauze, M.; Bankiewicz, K.; Tominaga, T. Convection-enhanced delivery of polyethylene glycol-coated liposomal doxorubicin: characterization and efficacy in rat intracranial glioma models Laboratory investigation. J. Neurosurg., 2008, 109, 867-873.
115. Ferguson, S.; Lesniak, M. S.; Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr. Drug Deliv., 2007, 4, 169-180 (Pubitemid 46557493)
116. Sandberg, D. I.; Edgar M. A.; Souweidane, M. M. Convectionenhanced delivery into the rat brainstem, J. Neurosurg., 2002, 96, 885-891.
117. Sonavanea G.; Tomodaa, K.; Makinoa, K. Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. Colloids and Surfaces B: Biointerfaces, 2008, 66, 274-280.
118. Lu, W.; Sun, Q.; Wan, J.; She, Z.; Jiang, X. G. Cationic albuminconjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res., 2006, 66, 1878-1887.
119. Chertok, B.; David, A. E.; Yang, V. C. Polyethyleneimine-modified Iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials. 2010, 31, 6317-6324.
120. William, H. F.; Rintaro, H. Intranasal delivery-A new therapeutic approach for brain tumors. US Neurology, 2009, 4, 43-44.
121. Mistry, A.; Stolnik, S.; Illum, I. Nanoparticles for direct nose-tobrain delivery of drugs. Int. J. Pharm., 2009, 379, 146-157.
122. Kumar, M.; Misra, A.; Babbar, A. K.; Mishra, A. K.; Mishra, P.; Patha, K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm., 2008, 358, 285-291.
123. Chatterjee, D. K.; Fong, L. H.; Zhang, Y. Nanoparticles in photodynamic therapy: An emerging paradigm. Adv. Drug Deliv. Rev., 2008, 60, 1627-1637.
124. Schmidt, M. H.; Meyer, G. A.; Reichert, K. W.; Cheng, J.; Krouwer, H. G.; Ozker, K.; Whelan, H. T. Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors. J. Neurooncol., 2004, 67, 201-207. (Pubitemid 38418269)
125. ® mediated fluorescence guided resection and photodynamic treatment as new therapeutic concept for malignant brain tumors. Med. Laser Appl., 2006, 21, 285-290. (Pubitemid 44740536)
126. Stepp, H.; Beck, T.; Pongratz, T.; Meinel, T.; Kreth, F. W.; Tonn, JCh.; Stummer, W. ALA and malignant glioma: fluorescenceguided resection and photodynamic treatment. J. Environ Pathol Toxicol Oncol., 2007, 26, 157-64. (Pubitemid 47295558)
127. Kulka, U.; Schaffer, M.; Siefert, A.; Schaffer, P. M.; Olsner, A.; Kasseb, K.; Hofstetter, A.; Dühmke, E.; Jori, G. Photofrin as a radiosensitizer in an in vitro cell survival assay. Biochem Biophys Res Commun., 2003, 311, 98-103 (Pubitemid 37297894)
128. Reddy, G. R.; Bhojani, M. S.; McConville, P.; Moody, J.; Moffat, B. A.; Hall, D. E.; Kim, G.; Koo Y. E.; Woolliscroft M. J.; Sugai, J. V.; Johnson, T. D.; Philbert, M. A.; Kopelman, R.; Rehemtulla, A.; Ross, B. D. Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors. Clin Cancer Res., 2006, 12, 6677-6686. (Pubitemid 44876835)
129. Gao, D.; Agayan, R. R.; Xu, H.; Philbert, M. A.; Kopelman, R. Nanoparticles for Two-Photon Photodynamic Therapy in Living Cells. Nano Lett., 2006, 23, 83-86.
130. Bechet, D. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol., 2008, 26, 612-621.
131. Kim, S.; Ohulchanskyy, T. Y.; Pudavar, H. E.; Pandey, R. K.; Prasad, P. N. Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. J. Am. Chem. Soc., 2007, 129, 2669-2675. (Pubitemid 46364075)
132. Rozhkova, E. A.; Ulasov, I.; Lai, B.; Dimitrijevic, N. M.; Lesniak, M. S.; Rajh, T. A High-performance nanobio photocatalyst for targeted brain cancer therapy. Nano Lett., 2009, 9, 3337-3342.
133. Hawthorne, M. F.; Lee, M. W.; A critical assessment of boron target compounds for boron neutron capture therapy. J. Neurooncol., 2003, 6, 33-45. (Pubitemid 36553116)
134. Bernard, J. A.; Procedures for implementation of MIT program on neutron capture therapy. Trans Am. Nucl. Soc., 1995, 72, 114.
135. Chen, W.; Mehta, S. C.; Robert Lu, D. Selective boron drug delivery to brain tumors for boron neutron capture therapy. Adv. Drug Deliv. Rev. 1997, 26, 231-247. (Pubitemid 27289536)
136. Yamamoto, T.; Nakai, K.; Matsumura, A. Boron neutron capture therapy for glioblastoma. Cancer Lett. 2008, 262, 143-152.
137. Barth, R. F.; Wu, G.; Yang, W.; Binns, P. J.; Riley, K. J.; Patel, H.; Coderre, J. A.; Tjarks, W.; Bandyopadhyaya, A. K.; Thirumamagal, B. T.; Ciesielski, M. J.; Fenstermaker, R. A. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl. Radiat Isot., 2004, 61, 899-903. (Pubitemid 39092637)
138. Doi, A.; Kawabata, S.; Iida, K.; Yokoyama, K.; Kajimoto, Y.; Kuroiwa, T.; Shirakawa, T.; Kirihata M.; Kasaoka, S.; Maruyama, K.; Kumada, H.; Sakurai, Y.; Masunaga, S.; Ono K.; Miyatake, S. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J. Neurooncol., 2008, 87, 287-294.
139. Oyewumi, M. O.; Mumper, R. J. Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy. Bioconjugate Chem., 2002, 13, 1328-1335. (Pubitemid 35420027)
140. Tokumitsu H.; Hiratsuka, J.; Sakurai, Y.; Kobayashi, T.; Ichikawa H.; Fukumori Y. Gadolinium neutron-capture therapy using novel gadopentetic acid-chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor. Cancer Lett., 2000, 150, 177-182. (Pubitemid 30125852)
141. Sharma, P.; Brown, S. C.; Walter, G.; Santra, S.; Scott, E.; Ichikawa, H.; Fukumori, Y.; Moudgil, B. M. Gd nanoparticulates: from magnetic resonance imaging to neutron capture therapy. Adv. Powder Technol., 2007, 18, 663-698. (Pubitemid 350112907)
142. Farokhzad, C. M.; Langer, R. Impact of Nanotechnology on Drug Delivery. ACS Nano., 2009, 3, 16-20.
143. Zhang, X.; Guo, Q.; Cui, D. Recent advances in nanotechnology applied to biosensors. Sensors, 2009, 9, 1033-1053.
144. Jianrong, C.; Yuqing, M.; Nongyue, H.; Xiaohua, W.; Sijiao, L. Nanotechnology and biosensors. Biotechnol. Adv., 2004, 22, 505-518. (Pubitemid 40047450)
145. Mi, L.; Zhang, X.; Yang, W.; Wang, L.; Huang, Q.; Fan, C.; Hu, J. Artificial nano-bio-complexes: effects of nanomaterials on biomolecular reactions and applications in biosensing and detection. J. Nanosci. Nanotechnol., 2009, 9, 2247-2255.
146. Bai, Y.; Ann, D. K.; Shen, W. C. Recombinant granulocyte colonystimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc. Natl Acad. Sci. USA., 2005, 102, 7292-7296. (Pubitemid 40696372)
147. Qian, Z. M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev., 2002, 54, 561-587. (Pubitemid 35351196)
148. Davis, M. E. The First Targeted Delivery of siRNA in Humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol. Pharm., 2009, 6, 659-668.
149. Kang, C.; Yuan, X.; Zhong, Y.; Pu P., Guo, Y.; Albadany, A.; Yu, S.; Zhang, Z.; Li, Y.; Chang, J.; Sheng, J. Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly (D, L-lactic acid) nanoparticles. Technol. Cancer Res Treat., 2009, 8, 61-70.
150. Gupta, Y.; Jain, A.; Jain, S. K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm Pharmacol., 2007, 59, 935-40. (Pubitemid 47051073)
151. Soni, V.; Kohli, D. V.; Jain, S. K. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J. Drug Target., 2008, 16, 73-78.
152. Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins Affecting
153. Gaillarda, P. J.; Brink, A.; de Boer, A. G. Diphtheria toxin receptortargeted brain drug delivery. Int. Congr Ser., 2005, 1277, 185-198. (Pubitemid 43693328)
154. Vivès, E.; Schmidt, J.; Pèlegrin, A. Cell-penetrating and celltargeting peptides in drug delivery. Biochim Biophysic Acta., 2008, 1786, 126-138.
155. Assa-Munt, N.; Jia, X.; Laakkonen, P.; Ruoslahti, E. Solution Structures and Integrin Binding Activities of an RGD Peptide with TwoIsomers. Biochemistry, 2001, 40, 2373-2378. (Pubitemid 32171709)
156. Chen, K.; Xie, J.; Xu, H.; Behera, D.; Michalski, M. H.; Biswal, S.; Wang, A.; Chen, X. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials, 2009, 30, 6912-6919.
157. Jung, J.; Solanki, A.; Memoli, K. A.; Kamei, K.; Kim, H.; Drahl, M. A.; Williams L. J.; Tseng, H. R.; Lee K. Selective inhibition of human brain tumor cell proliferation via multifunctional quantum dot-based siRNA delivery. Angew. Chem. Int. Ed Engl., 2010, 49, 103-107.
158. Gupta B.; Levchenko, T. S.; Torchilin, V. P. TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncology Res., 2007, 16, 351-9. (Pubitemid 47413251)
159. Adams, G. P.; Weiner, L. M. Monoclonal antibody therapy of cancer. Nat. Biotechnol., 2005, 23, 1147-1157. (Pubitemid 41486396)
160. Gosk, S.; Vermehren, C.; Storm, G.; Moos, T. Targeting antitransferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb Blood Flow Metab., 2004, 24, 1193-1204. (Pubitemid 39482480)
161. Wang, C. H.; Chiou, S. H.; Chou, C. P.; Chen, Y. C.; Huang, Y. J.; Peng, C. A. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes with CD133 monoclonal antibody. Nanomedicne. 2011, 7(1), 69-79.
162. James, W. Aptamers. Encylopedia of Analytical chemistry, 2000, 4, 848-871.
163. Hamula, C. A.; Guthrie, J. W.; Zhang, H.; Li, X. F.; Le, X. C. Selection and analytical applications of aptamers. Trends Analyt Chem., 2006, 25, 681-691. (Pubitemid 44109900)
164. Guo, K. T.; Paul, A.; Schichor, C.; Ziemer, G.; Wendel, H. P. CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int. J. Mol. Sci., 2008, 9, 668-678. (Pubitemid 351631122)
165. Shangguan, D.; Li, Y.; Tang, Z.; Cao, Z. C.; Chen, H. W.; Mallikaratchy, P.; Sefah, K.; Chaoyong Yang, C. J.; Tan, W. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA., 2006, 103, 11838-11843. (Pubitemid 44215773)
166. Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Wang, A. Z.; Langer, R.; Farokhzad, O. Nanotechnology and Aptamers: application in drug delivery. Trends Biotechnol., 2008, 26, 442-449.
167. Wang, H.; Yang, R.; Yang, L.; Tan, W. Nucleic acid conjugated nanomaterials for enhanced molecular recognition. ACS Nano., 2009, 3, 2451-2460.
168. Chen X.; Estévez M. C.; Zhu, Z.; Huang Y. F.; Chen, Y.; Wang, L.; Tan, W. Using aptamer conjugated fluorescence resonance energy transfer nanoparticles for multiplexed cancer cell monitoring. Anal Chem., 2009, 81, 7-14.
169. Li, Z.; Huang, P.; He, R.; Lin, J.; Yang, S.; Zhang, X.; Ren, Q.; Cui, D. Aptamer-conjugated dendrimer-modified quantum dots for cancer cell targeting and imaging. Mater Lett., 2010, 64, 375-378.